Amneal Pharmaceuticals, Class Stock Today
| AMRX Stock | USD 8.35 0.10 1.21% |
Performance0 of 100
| Odds Of DistressLess than 33
|
Amneal Pharmaceuticals, is trading at 8.35 as of the 28th of November 2024; that is 1.21 percent up since the beginning of the trading day. The stock's open price was 8.25. Amneal Pharmaceuticals, has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Amneal Pharmaceuticals, Class are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of January 2009 | Category Healthcare | Classification Health Care |
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. The company has 309.84 M outstanding shares of which 3.5 M shares are presently shorted by private and institutional investors with about 4.23 trading days to cover. More on Amneal Pharmaceuticals, Class
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Amneal Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Chintu Patel | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAmneal Pharmaceuticals, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amneal Pharmaceuticals,'s financial leverage. It provides some insight into what part of Amneal Pharmaceuticals,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amneal Pharmaceuticals, Class (AMRX) is traded on New York Stock Exchange in USA and employs 7,850 people. Amneal Pharmaceuticals, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.81 B. Amneal Pharmaceuticals, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 309.84 M outstanding shares of which 3.5 M shares are presently shorted by private and institutional investors with about 4.23 trading days to cover.
Amneal Pharmaceuticals, Class currently holds about 87.33 M in cash with 345.58 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.58.
Check Amneal Pharmaceuticals, Probability Of Bankruptcy
Ownership AllocationAmneal Pharmaceuticals, holds a total of 309.84 Million outstanding shares. Amneal Pharmaceuticals, Class retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Amneal Ownership Details
Amneal Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Nuveen Asset Management, Llc | 2024-06-30 | 2.5 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.1 M | |
| Blackbarn Capital Partners Lp | 2024-06-30 | 2 M | |
| Fosun International Ltd | 2024-09-30 | 1.7 M | |
| Northern Trust Corp | 2024-09-30 | 1.6 M | |
| Hennessy Advisors, Inc. | 2024-09-30 | 1.6 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.4 M | |
| Woodline Partners Lp | 2024-06-30 | 1.3 M | |
| Ubs Group Ag | 2024-06-30 | 21.8 M | |
| Vanguard Group Inc | 2024-09-30 | 14.6 M |
Amneal Pharmaceuticals, Historical Income Statement
Amneal Stock Against Markets
Already Invested in Amneal Pharmaceuticals, Class?
The danger of trading Amneal Pharmaceuticals, Class is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amneal Pharmaceuticals, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amneal Pharmaceuticals,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amneal Pharmaceuticals, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.